Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

1. Invivyd Inc (NASDAQ:IVVD)

Number of Hedge Fund Holders In Q4 2024: 14

Invivyd Inc (NASDAQ:IVVD) is a biopharmaceutical company that makes antibody-based therapies for infectious diseases.

The stock is up significantly so far in 2025 after the announcement of positive Phase 1/2 clinical data for VYD2311. This monoclonal antibody candidate is designed to be a better alternative to COVID-19 vaccination for the broad population.

The clinical trial showed more favorable safety and tolerability compared to vaccines, with no activation of the subject immune systems, and demonstrated potential as a novel, potent, long-acting COVID-19 treatment option.

On the same day, Invivyd announced preliminary fourth quarter 2024 financial results showing strong revenue growth. Their PEMGARDA™ (pemivibart) product grew revenue by 48% to $13.8 million.

The consensus price target of $7.89 implies 536.09% upside.

IVVD is up 179.85% year-to-date.

While we acknowledge the potential of IVVD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IVVD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: Why These 15 E-Commerce Stocks Are Skyrocketing So Far In 2025 and Why These 15 Insurance Stocks Are Skyrocketing So Far In 2025

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.